ERBB2 and breast cancer: There may be an advantage to combining an anthracycline with a taxane in women with HER2-positive tumors; if so, epirubicin plus paclitaxel may be a particularly effective regimen against HER2-positive breast cancer, whereas HER2 status may not influence the likelihood of a response to paclitaxel given alone.